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Background: Secondary pulmonary alveolar proteinosis (sPAP) is a very rare lung disorder comprising
approximately 10% of cases of acquired PAP. Hematological disorders are the most common underlying conditions
of sPAP, of which 74% of cases demonstrate myelodysplastic syndrome (MDS). However, the impact of sPAP on the
prognosis of underlying MDS remains unknown. The purpose of this study was to evaluate whether development
of sPAP worsens the prognosis of MDS.
Methods: Thirty-one cases of sPAP and underlying MDS were retrospectively classified into mild and severe cases
consisting of very low-/low-risk groups and intermediate-/high-/very high-risk groups at the time of diagnosis of
MDS, according to the prognostic scoring system based on the World Health Organization classification. Next, we
compared the characteristics, disease duration, cumulative survival, and prognostic factors of the groups.
Results: In contrast to previous reports on the prognosis of MDS, we found that the cumulative survival probability
for mild MDS patients was similar to that in severe MDS patients. This is likely due to the poor prognosis of patients
with mild MDS, whose 2-year survival rate was 46.2%. Notably, 75% and 62.5% of patients who died developed fatal
infectious diseases and exacerbation of PAP, respectively, suggesting that the progression of PAP per se and/or
PAP-associated infection contributed to poor prognosis. The use of corticosteroid therapy and a diffusing capacity
of the lung for carbon monoxide of less than 44% were predictive of poor prognosis.
Conclusion: Development of sPAP during the course of MDS may be an important adverse risk factor in prognosis
of patients with mild MDS.
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Pulmonary alveolar proteinosis (PAP), a rare disorder
predominantly affecting the lungs, is characterized by
accumulation of surfactant lipids and proteins in the al-
veoli and terminal bronchioles [1]. PAP is clinically clas-
sified into three distinct forms, namely, autoimmune,
secondary, and congenital PAP [2]. Autoimmune PAP is
associated with disruption of granulocyte/macrophage
colony-stimulating factor (GM-CSF) signaling caused by
high levels of GM-CSF autoantibody in the lungs [3].
Secondary PAP (sPAP) results from underlying diseases
that presumably impair surfactant clearance because of
abnormal numbers and functions of alveolar macrophages
(AMs). Of the 40 cases of sPAP previously reported by
our group [4], 88% (n = 35) involved hematological disor-
ders as underlying diseases. The probability of survival at
two years was 46% in cases with sPAP complicating
hematological disorders. The median survival time for all
cases including 17 patients who died within two years of
the sPAP diagnosis was 16 months. Although myelodys-
plastic syndrome (MDS) is the most frequent underlying
disease of sPAP (n = 26, 65%), little information is available
on the prognostic impact of development of sPAP on pa-
tient outcome.
MDS, a group of clonal hematological stem-cell disor-
ders with ineffective myeloid hematopoiesis and varying
degrees of bone marrow failure, is associated with a
significant risk of progression to acute myeloid leuke-
mia (AML). Clinical manifestations are variable, from
indolent conditions with near-normal life expectancy
to forms that rapidly develop into AML [5]. Clari-
fying much of this heterogeneity, the World Health
Organization (WHO) developed a classifications of MDS
based on the presence of unilineage or multilineage
dysplasia, bone marrow blast cell count, and cytogenetic
features: refractory anemia (RA), RA with ringed side-
roblasts (RARS), refractory cytopenia with multilineage
dysplasia (RCMD), RCMD with ringed sideroblasts
(RCMD-RS), RA with excess of blasts-1 (RAEB-1), and
RA with excess of blasts-2 (RAEB-2) [6]. In 2007,
Malcovati et al. developed a new prognostic scoring
system (WHO classification-based prognostic scoring
system (WPSS)) according to WHO subgroup, karyo-
type, and transfusion requirement. Through this system,
cases with MDS are classified into very low-, low-,
intermediate-, high-, or very high-risk groups [7]. WPSS
is a dynamic system that accurately predicts the survival
and risk of leukemic evolution in MDS patients at any
time during the course of their disease. This time-
dependent system seems particularly useful for lower-risk
patients and for implementing risk-adapted treatment
strategies.
Given the validation of WPSS criteria as a prognostic
indicator for the course of MDS, it is applicable inprognosis evaluation of MDS complicated by PAP
(MDS/sPAP). In the present study, we evaluated this
issue for the first time and found that development of




Thirty-one patients in Japan who were diagnosed with
sPAP with underlying MDS from July 1999 to June
2013 were evaluated. We obtained agreement from all
treating physicians for each identified case, according
to the Guidelines for Epidemiological Studies by The
Ministry of Health, Labour, and Welfare. This was a
retrospective cohort study approved by the Ethical
Board of Kyorin University (H23-085-01). Cases, part of
which were reported previously, were identified retro-
spectively [8-18].
Diagnosis
Diagnosis of MDS was made according to the 2002
WHO criteria [6]. One patient with unclassified MDS,
two patients with myelofibrosis, and two patients with
20% marrow blasts who were considered as having AML
were excluded from the study. MDS with isolated
chromosome 5 deletion (del(5q)) and marrow blasts
of <5% were included. Next, the patients were classified
into RA, RARS, RCMD, RAEB-1, and RAEB-2 groups.
Karyotypes were classified by using the International
System for Cytogenetic Nomenclature Criteria [19].
Diagnosis of PAP was based on the following criteria: 1.
histopathological findings from specimens obtained by
surgical biopsy or transbronchial lung biopsy, or milk-
like appearance with typical cytological findings from
bronchoalveolar lavage fluid (BALF); 2. typical high-
resolution computed tomography (HRCT) findings for
PAP, such as ground glass opacity, consolidation, and
interlobular septal thickening; and 3. negative result for
serum GM-CSF autoantibody.
Classification by WPSS
The WPSS score was calculated according to the
method of Malcovati et al. [7] The score was calculated
from the data of WHO subgroups (RA/RARS/5q–,
RCMD/RCMD-RS, RAEB-1, and RAEB-2), karyotype
abnormalities categorized according to the International
Prognostic Scoring System [20], and transfusion require-
ment. The same weight (score of ≥1) was assigned to
each variable for WHO subgroup, karyotype, and trans-
fusion requirement. Based on the score, patients were
classified according to the following five risk groups: very
low (score = 0), low (score = 1), intermediate (score = 2),
high (score = 3 to 4), and very high (score = 5 to 6). Trans-
fusion dependency was defined as having at least one
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period of four months.
Statistical analysis
The cumulative probability of survival and risk of progres-
sion to leukemia were estimated by using the Kaplan–Meier
method. Patients undergoing transplantation treatment
were censored at the time of the procedure in order to
exclude any potential source of bias due to differential
treatment. Variable data were analyzed through Kaplan–
Meier methods to estimate the cumulative probabilities
of overall survival. The difference in the cumulative
probabilities within subcategories of patients was com-
pared by using two-sided log rank test. Survival analyze
was performed using Cox proportional model with
time-dependent covariates to assess the effect of the
variables of interest on overall survival.
Numeric data were evaluated for normal distribu-
tion and for equal variance by using the Kolmogorov–
Smirnov test and Levene’s median test, respectively.
Nonparametric data are presented as medians. Categor-
ical data are presented as a percentage of the total or
numerically, as appropriate. Statistical comparisons of
nonparametric data were compared through the Wilcoxon
test. Comparisons of categorical data were made with
chi-square or Fischer’s exact tests. All tests were two-
sided. Statistical significance was indicated by p values
of <0.05. Data were analyzed by using SPSS 17.0
software for Windows.
Results
From September 1999 to May 2013, we centrally ana-
lyzed for GM-CSF autoantibody in the sera of 619PAP diagnosed in Jap
N= 619











Figure 1 Disposition of patients with pulmonary alveolar proteinosis
according to the presence or absence of granulocyte/macrophage-colony
presence or absence of an underlying disease known to cause PAP.Japanese cases that had been diagnosed as PAP. Of those
cases, 561 were positive for the antibody and 58 were
negative. In the cases negative for GM-CSF antibody, 51
demonstrated obvious underlying diseases such as
hematological disorders, autoimmune diseases, and in-
fectious diseases. As shown in Figure 1, hematological
disorders were the most common underlying disease, 31
cases of which involved MDS. These cases were investi-
gated retrospectively in this study.
Demographic data are shown in Table 1. Diagnosis of
MDS was performed in accordance with WHO criteria;
19, 1, 5, 3, and 3 cases were RA, RARS, RCMD, RAEB-1,
and RAEB-2, respectively. Karyotyping revealed 2 cases of
“high-riskes of g e, 24 cases of “intermediate-riskmediatef,
and 5 cases of “low-risks disease. As previously reported
[10], there was over-representation of trisomy 8, as it was
present in 16 cases (51.6%). RBC transfusion dependency
was observed in 11 cases.
PAP was diagnosed on the basis of the BALF and
HRCT results in 23 cases and by surgical biopsy and
HRCT in eight cases. In 23 cases, diagnosis of MDS was
done before diagnosis of PAP, whereas eight cases were
diagnosed simultaneously.
According to the WPSS, the cases were classified into 2,
11, 7, 9, and 2 cases of very low-, low-, intermediate-, high-
, and very high-risk groups, respectively. For statistical ana-
lysis, very low-/low-risk groups and intermediate-/high-/
very high-risk groups were categorized as “mild MDS”
and “severe MDS” DSere iz, respectively (Table 1).
There was no difference in sex and age at the diagnosis
of MDS and in hemoglobin concentration, absolute
neutrophil count, and platelet count between mild and
severe MDS cases. Then, the median age at diagnosis ofan
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(PAP) who were enrolled into this study. Participants were stratified
stimulating factor (GM-CSF) autoantibody, and then according to the
Table 1 Demographic data at diagnosis of MDS in each group classified according to the WPSS
<WPSS risk groups>
<Very low + low > <Inter − +high + very high>
Median (min.–max.) Total Mild MDS Severe MDS p value
(n = 31) (n = 13) (n = 18)
Sex (M/F) 19/12 7/6 12/6 0.71
Age at Dx of MDS 50 (27–75) 45 (30–67) 50 (27–75) 0.54
HbG (g/dl) 9.4 (4.8–16.4) 11.4 (5.5–16.4) 9.0 (4.8–13.9) 0.06
ANC (× 109/L) 1.84 (0.01–7.54) 1.46 (0.45–6.97) 2.74 (0.01–7.54) 0.68
PLT (× 109/L) 65 (6–219) 45 (14–219) 69 (6–196) 0.31
WHO subgroup: n (%)
RA/RARS 20 (65) 13 (100) 7 (39) <0.001
RCMD 5 (16) 0 (0) 5 (28) 0.058
RAEB-1,2 6 (19) 0 (0) 6 (33) 0.02
Karyotype*: n (%)
Good type 2 (7) 2 (15) 0 0.16
Intermediate type 24 (77) 11 (85) 13 (72) 0.66
Poor type 5 (16) 0 (0) 5 (28) 0.058
RBC transfusion dependency**: n (%) 11 (35) 0 (0) 11 (61) <0.001
(*) Cytogenetics was as follows. Good type: normal, −Y, del(5q), del(20q); poor type: complex (≥ three abnormalities), chromosome 7 anomalies; and intermediate
type: other abnormalities.
(**) RBC transfusion dependency was defined as having at least one RBC transfusion every eight weeks over a period of four months. ANC, absolute neutrophil
count; Dx, diagnosis; HbG, hemoglobin; MDS, myelodysplastic syndrome; PLT, platelets; RA, refractory anemia; RAEB, refractory anemia with blasts; RARS, refractory
anemia with ringed sideroblasts; RBC, red blood cell; RCMD, refractory anemia with multilineage dysplasia; WHO, World Health Organization; WPSS, WHO
classification-based prognostic scoring system.
Table 2 Clinical status at death (n = 17)
WPSS at diagnosis WHO criteria at diagnosis of MDS AML progression Progression of PAP Pneumonia
No. 6 (35.3%) 11 (64.7%) 11 (64.7%)
Mild MDS 1 Very low + low RA ●
2 RA ●
3 RA ● ●




Severe MDS 8 Intermediate RA ●
9 RA ● ●
10 RA ● ●
11 RA ● ● ●
12 RA ● ●
13 RCMD ●
14 High + very high RA ● ●
15 RCMD ● ●
16 RAEB-1 ● ●
17 RAEB-2 ● ●
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; PAP, pulmonary alveolar proteinosis; RA, refractory anemia; RAEB, refractory anemia with blasts;
RCMD, refractory anemia with multilineage dysplasia; WHO, World Health Organization; WPSS, WHO classification-based prognostic scoring system.
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tomatic, with the most common symptoms being fever
(45%), dyspnea on effort (42%), and cough (42%). The
value of serum Krebs von den Lungen-6 (KL-6) and
surfactant protein-D (SP-D) were elevated, and the dif-
fusing capacities of the lung for carbon monoxide (%
DLco) were very low in the absence of ventilation dis-
order in pulmonary function tests. There was no differ-
ence in the frequency of respiratory symptoms between
patients with mild MDS and those with severe MDS.
Serum biomarkers and pulmonary function tests showed
no significant difference between the two groups.
Follow-up periods after diagnosis of MDS ranged












































Figure 2 Disease duration of secondary PAP in patients with MDS. A:
pulmonary alveolar proteinosis (sPAP). The horizontal axis indicates the mo
column and closed column indicate the duration of disease respectively be
marked by † and the case that underwent transplantation therapy is marke
PAP (sPAP) in patient groups with mild myelodysplastic syndrome (MDS) (n
month after the diagnosis of sPAP, and the vertical axis indicates the cumupatients (Additional file 1: Figure S1 and Additional file
2: Figure S2). During the follow-up period, 7 patients
with mild MDS and 10 patients with severe MDS died,
and 2 patients with mild MDS and 4 patients with se-
vere MDS progressed to AML (Table 2). Two and five
patients in the mild MDS and severe MDS groups, re-
spectively, underwent transplantation therapies. They
were censored at the time of the procedure. The dur-
ation from diagnosis of MDS to diagnosis of sPAP was
variable, ranging from 0 to 168 months in the mild
MDS group and from 0 to 228 months in the severe
MDS group (Figure 2A). The median duration of MDS
prior to diagnosis of sPAP in the mild MDS group









150 200 250 (months)
Duration of disease before or after the diagnosis of secondary
nth after the diagnosis of myelodysplastic syndrome. The open
fore and after the diagnosis of sPAP. The case that resulted in death is
d by *. B: Cumulative survival probability after diagnosis of secondary
= 13) and severe MDS (n = 18). The horizontal axis indicates the
lative survival probability.
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one in the severe MDS group survived for more than five
years after diagnosis of sPAP. Of those, spontaneous
remission of sPAP occurred in three cases.
A previous report [7] demonstrated that prediction of
survival was dependent on the severity of MDS (as de-
fined by WPSS) at any time of the disease. In contrast,
patients with mild MDS in our study had cumulative
survival probability similar to that of patients with severe
MDS (Figure 2B, p = 0.827). This similarity may be due
to poor prognosis of mild MDS after diagnosis of PAP.
The cumulative survival probability curves of mild
and severe MDS groups with median survivals of 13 and
15 months, respectively, are comparable. Concerning
causes for the death of seven patients in the mild MDS
group were progression to AML in two cases, PAP ex-
acerbation in four cases, and fatal infectious disease in
three cases (Table 2). Concerning causes for the death ofTable 3 Univariate analysis of overall survival after diagnosis
Variable at diagnosis of sPAP (n) 75% of OS (months)
Age: 51 yrs or younger 16 8
Older than 52 yrs 15 10
Gender: Male 19 10
Female 12 11
MDS group: mild 13 10
severe 18 11
Symptoms: (−) 5 26
(+) 26 6
Dx procedure: Bronchoscopy 23 11
Surgical biopsy 8 15
Respiratory failure: (−) 21 11
(+) 10 5
Use of corticosteroid: (−) 16 16
(+) 15 10
Serum KL-6 (U/ml): < 1960 16 13
1960 ≦ 15 5
Serum SP-D (ng/ml): < 147 15 10
147 ≦ 15 8
Serum SP-A (ng/ml): < 79 16 11
79 ≦ 14 5
%VC: 87 ≦ 11 15
< 87 11 8
FEV1%: 86 ≦ 12 8
< 86 10 13
%DLco: 44 ≦ 9 21
< 44 8 5
CI indicates confidence interval; OS, overall survival; DLco, diffusing capacity of the
hazard ratio; KL-6, krebs von den lungen-6; MDS, myelodysplastic syndrome; SP-A, s
surfactant protein -D; VC, vital capacity.10 patients in the severe MDS group were progression
to AML in 4 cases, PAP exacerbation in 7 cases, and
fatal infectious disease in 8 cases. Fatal infectious dis-
eases consistently arose from severe pneumonia with
(n = 4) or without systemic sepsis, suggesting that pro-
gression of PAP was the major cause of death in both
mild and severe MDS patients. These results suggest
that occurrence of sPAP principally reduced the survival
of patients with mild MDS. Pathogens isolated in the
fatal cases were identified as Aspergillus species (four
cases), Pseudomonas aeruginosa (four cases), and non-
tuberculosis Mycobacterium species (four cases).
By performing univariate analysis using Cox propor-
tional model we then searched for potential prognostic
factors. Age, sex, respiratory symptoms, history of respira-
tory failure, diagnostic procedure for sPAP, and MDS
group (mild or severe), were not associated with survival
at the time of diagnosis of sPAP (Table 3). Treatment withof sPAP in MDS
50% of OS (months) HR (95% CI) P value
16
15 1.29 (0.48-3.41) 0.607
16
21 1.12 (0.43-2.94) 0.804
15
16 1.11 (0.42-2.95) 0.830
26
15 1.50 (0.33-6.65) 0.592
13
26 0.69 (0.23-2.04) 0.507
26
10 2.18 (0.77-6.22) 0.142
80
13 3.20 (1.09-9.38) 0.034
26
15 1.52 (0.58-4.00) 0.389
26
15 1.80 (0.62-5.22) 0.278
26
15 2.79 (0.965-8.06) 0.058
34
15 3.27 (0.79-13.52) 0.101
16
34 0.52 (0.14-1.87) 0.322
34
13 9.98 (1.03-96.11) 0.046
lung for carbon monoxide; Dx, diagnosis; FEV, forced expiratory volume; HR,
urfactant protein -A; sPAP, secondary pulmonary alveolar proteinosis; SP-D,
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0.024) (Figure 3A). However, the number of patients
treated with steroid therapy did not differ between mild
and severe MDS groups. A %DLco of <44% (Figure 3B)
predicted poor prognosis (p = 0.019), whereas %vital ca-
pacity (%VC), forced expiratory volume (FEV) 1.0%, serum
KL-6, SP-D, and surfactant protein-A (SP-A) did not.
Discussion
For the first time, we evaluated the prognosis of MDS/








































%DLco < 44% (n=8)
Figure 3 Risk factors for the prognosis of secondary PAP in patients w
secondary PAP (sPAP) in myelodysplastic syndrome (MDS) cases with stero
The horizontal axis indicates the month after the diagnosis of sPAP, and th
of cases that received steroid therapy in the mild and severe MDS groups
probability after diagnosis of secondary PAP (sPAP) in myelodysplastic synd
monoxide (%DLco) of <44% (n = 8) and in MDS cases with%DLco of >44%
sPAP, and the vertical axis indicates the cumulative survival probability.and severe MDS as classified according to WPSS cri-
teria. Our data demonstrate that the duration from diag-
nosis of MDS to diagnosis of sPAP was longer in mild
MDS than that in severe MDS, but the survival probabi-
lity was similar after the diagnosis of sPAP regardless of
MDS severity. As a whole, occurrence of PAP appeared
to worsen the prognosis of patients with mild MDS. This
result is supported by the fact that the major cause
of death was not MDS-associated but rather sPAP-
associated respiratory failure or infections. Prior to our






ith MDS. A: Cumulative survival probability after diagnosis of
id therapy (n = 15) and in MDS cases without steroid therapy (n = 16).
e vertical axis indicates the cumulative survival probability. The number
were six (46%) and nine (59%), respectively. B: Cumulative survival
rome (MDS) cases with diffusing capacity of the lung for carbon
(n = 9). The horizontal axis indicates month after the diagnosis of
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whereas only two publications report multiple cases
[8,25]. The clinical course described in these reports
suggest a poor prognosis for MDS/sPAP patients, but no
prior report clearly quantifies the outlook for these pa-
tients and compares this to a predicted outcome by
using validated prognostic scores such as WPSS. MDS/
sPAP is so rare a disease that neither pulmonologists
nor hematologists encounter such patients very often. In
fact, in more than 10 years, 2 to 5 cases were diagnosed
as MDS/sPAP annually in our analyses for serum GM-CSF
autoantibody in over 600 diagnosed PAP cases from
all over Japan; thus, we have finally reached cumula-
tive 31 cases with MDS/sPAP.
According to the WHO criteria, 20 of the 31 cases
were RA/RARS, 5 cases were RCMD, and 6 cases were
RAEB1-2. The proportion of the number for each sub-
type in the total number of cases was comparable to
literature data in terms of frequency and subtype distri-
bution, suggesting that the risk of PAP complicating
MDS is similar regardless of the subtype of MDS. It is
speculated that AMs in patients with MDS derive from
abnormal bone marrow precursor cells and are defec-
tive in both surfactant homeostasis and host defense,
hence the progression of PAP and PAP-associated in-
fections even in cases with mild MDS. Previous studies
reported that in the absence of complicating sPAP,
the five-year survival probability for patients with RA
and RARS was 74% [26], whereas our cases with RA
plus RARS had substantially inferior prognosis (0.69)
(Additional file 2: Figure S2).
It is noteworthy that treatment with corticosteroids
was associated with a markedly inferior prognosis. In
Japan, steroid therapy often has been used for PAP but
no evidence of its efficacy has been found. To our sur-
prise, 15 of 31 cases had undergone steroid therapy du-
ring the course of sPAP. Our data reveal that steroid-
treated patients had worse prognosis than did patients
without steroid therapy. Given that the predominant
cause of death was infective complications potentially
exacerbated by steroid-related immunosuppression, these
data clearly caution against the use of steroid therapy in
such patients.
Treatment of MDS/sPAP should be directed toward
the underlying malignancy, i.e., MDS. It should also
aim at restoring hematopoietic function, either through
allogeneic bone marrow transplant, which has curative
potential for both MDS and sPAP, or through hypo-
methylating agent therapy for MDS, which can restore
numerical hematologic parameters. However, functional
cellular defects will likely remain, as such therapy does
not necessarily eradicate the underlying clone, but rather
enhances cellular differentiation [27,28]. Nevertheless,
seven cases with MDS/sPAP to date in our cohorthad undergone transplantation therapy. Of those, three
patients died of pneumonia within three months of
the transplantation therapy. Therefore, we do not have
any convincing evidence to recommend transplantation
therapy in the early stages of the disease. Although
whole-lung lavage and segmental bronchial lavage were
performed in 10 patients, only 3 cases showed the effi-
cacy of lung-lavage therapy.
Infection often coexists with MDS/sPAP, although the
causal relationship between PAP and infection is not
clear. Superimposed infection accounts for a significant
degree of morbidity and mortality in patients with sPAP.
In the present study, 11 among 17 cases with fatal out-
comes developed fatal infectious diseases. Considering
that this complication was observed in the mild MDS
and severe MDS groups, pneumonia accompanied with
sPAP might be the trigger of fatal infection. Neverthe-
less, the present number of cases (31) is too small for
accurate prognosis evaluation of MDS/sPAP; future
international collaboration may be necessary to over-
come this difficulty.
Conclusions
Complication of sPAP is an important risk factor in
the prognosis of MDS. We believe that the present
data will contribute to the management and treatment
of the disease.
Additional files
Additional file 1: Figure S1. Survival curves after diagnosis of MDS in
each mild and severe MDS.
Additional file 2: Figure S2. Survival curves in each MDS groups
classified by WHO-criteria.
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